KRAS and neoplasm: Mutant KRAS proteins are insensitive to GAP-induced GTP hydrolysis, which is linked to many aspects of tumor initiation and progression, including deregulation of key signal transduction pathways, altered metabolism, metastasis and drug resistance (50).